Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-5307 Phase II/III study in acromegaly and pituitary gigantism
jRCT2031230524Phase 3Completed
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paltusotine in acromegaly and gigantism (3 arms), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoints: Change from baseline in serum IGF-1 concentration at end of Treatment Period I and Proportion of subjects achieving normal IGF-1 at end of Treatment Period II. Started Mar 2024; status: completed.
02
Drugs
paltusotine
03
Conditions
acromegalygigantism
Beyond the preview
Go deeper on jRCT2031230524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230524.